Below is a sample of existing clinical evidence:
NERVE INJURY
“Administration of AFMSCs (Amniotic Fluid-derived Mesenchymal Stem Cells) led to improvements in neurobehavior and expression of regeneration markers. Intravenous administration of AFMSCs may be a promising alternative treatment strategy in peripheral nerve disorder.”
“Administration of AFMSCs (Amniotic Fluid-derived Mesenchymal Stem Cells) led to improvements in neurobehavior and expression of regeneration markers. Intravenous administration of AFMSCs may be a promising alternative treatment strategy in peripheral nerve disorder.”
– “Dual regeneration of muscle and nerve by intravenous administration of human amniotic fluid–derived mesenchymal stem cells regulated by stromal cell–derived factor-1a in a sciatic nerve injury model,” Yang et al, Journal of Neurosurgery, 2012